Background: Efavirenz, a non-nucleoside reverse transcriptase inhibitor, is a preferred drug for the treatment of HIV-positive patients. However, one of its adverse effects is gynecomastia, which not ...

Abstract: In the hospital environment, authentication is required to allow patients to access constrained areas such as dedicated patient rooms. Identification is necessary for any authentication ...

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...

DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ...